Bavarian Nordic — August 2021
-
Ali Salanti (Adaptvac) skriver på Linkedin:
Great news on our SARS-COV-2 vaccine presented as a novel virus like particle formulation. First human trial data show that the vaccine is very well tolerated. The clinical site reports that “In contrast to licensed SARS-CoV-2 vaccines, ABNCoV2’s safety profile is comparable to licensed protein-based vaccine such as hepatitis B vaccines and well tolerated even at doses beyond those that induce maximal immune-responses”. -
But most importantly the vaccine induces very high antibody responses (up to 12 fold compared to convalescent sera). Responses that are several fold higher than best in class mRNA vaccines ????. The potency of the vaccine platform is highlighted by the fact that even in the absence of adjuvants do we get high tittered responses, and even at the low vaccine doses.
-
We originally believed the precise positioning of the ACE2 binding part of the SARS-COV-2 receptor binding domain on the rigid surface of the virus like particle should results in a focused anti-RBD response with superior virus neutralization efficacy, and indeed our data generated together with Århus University show that we effectively neutralize the delta variant but more importantly we also very effectively (and importantly, better than
-
convalescence sera and mRNA vaccine induced sera) neutralize the escape variants represented in our study including the Beta variant. This vaccine(candidate) is also characterized by being rock stable even at ambient temperatures for longer time periods, and combining this with superior antibody responses we hope such a vaccine can not only be deployed in this part of the world as a booster vaccine, but also in parts of the world where the cold chain cannot be assured. Sadly, only 1% of people
-
-
Dansk vaccine har lang vej til godkendelse trods stærke data
https://www.proinvestor.com/investornyt/688439/dansk-vaccine-har-lang-vej-til-godkendelse-trods-staerke-data -
Zea - det vil blive modtaget med stor taknemlighed hvis nødpennen viser gode omsætningstakter. Vi kan håber lidt af sløret bliver løft sammen med ledelsens forventninger. Det er dog vist for tidligt at måle nogen reel omsætning før Q3.
-
bliver spændende på torsdag
-
-
Man kunne forestille sig det er denne type aftale regeringen er ude efter (ekspertpanelet anbefalede jo at gå efter m-RNA) https://endpts.com/moderna-strikes-a-deal-with-canada-to-build-an-mrna-manufacturing-center-and-its-looking-for-more-global-pacts-just-like-it/
-
Du siger, at det efter de første vaccineforsøg bliver lettere for jer at få finansieringen på plads. Så hvor forventer du, at pengene til fase 3-forsøgene vil komme fra?
»Det kan jeg ikke kommentere, men siden vi offentliggjorde resultaterne mandag morgen, har der været en kæmpeinteresse fra alle sider. Investorer, vi aldrig har talt med, har pludselig fået øjnene op for os, og det samme gælder andre med investeringsmuligheder,« siger Rolf Sass Sørensen.
-
BAVA: det er en interssant artikel du citere fra
https://finans.dk/erhverv/ECE13189142/bavarianstifter-asger-aamund-afviser-at-komme-med-finansiering-til-danske-vaccineforsoeg/?ctxref=forside mon ikke det nu bliver letter at sikre finaseringen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind